Medical Licensing (MD/DO) · Independent exam preparation
Pediatric Hematology-Oncology Initial Certification Examination Study Guide
Practise pediatric blood-disorder diagnosis, cancer risk stratification, urgent supportive care, transplant decisions, and evidence interpretation for ABP certification.
By CertMedbry · Updated 16 October 2026
Distinguish destructive from production anemias, select bleeding-disorder tests, recognize oncologic emergencies, and interpret tumor biology, transplant complications, and clinical evidence. These 60 selected concepts connect mechanisms with decisions across all 11 initial-certification domains. The ABP Pediatric Hematology-Oncology Content Outline, effective April 1, 2019, defines the full examination scope; this selective guide does not replace its detailed topic list.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide address?
The pathway is ABP initial certification in Pediatric Hematology-Oncology, a recognized physician subspecialty. ASPHO describes prior general pediatrics training and certification followed by pediatric hematology-oncology fellowship. This guide uses the initial-certification blueprint column.
ASPHO: Certification in Pediatric Hematology/Oncology · ABMS: American Board of Pediatrics
Which blueprint and effective date apply?
The ABP-authored outline is effective for examinations administered beginning April 1, 2019. ASPHO continues to identify that outline as applicable. A separately dated 2026 revision is not established by these sources.
ABP Pediatric Hematology-Oncology Content Outline · ASPHO: Certification in Pediatric Hematology/Oncology
How is initial-certification content weighted?
Approximate domain weights are Erythrocytes 13%; Leukocytes 4%; Platelets 7%; Hemostasis/Thrombosis 10%; Bone Marrow Failure 5%; Transfusion Medicine 5%; General Oncology Issues 14%; Hematologic Malignancies 11%; Solid Tumors 17%; Hematopoietic Stem-Cell Transplant (HSCT) 9%; and Core Knowledge in Scholarly Activities 5%. Actual examinations may vary. The guide, questions, and cards approximate these weights while covering every domain.
Which clinical tasks does the blueprint emphasize?
The approximate task weights are basic science and pathophysiology 17%, epidemiology and risk assessment 13%, diagnosis 37%, and management and treatment 33%. Practise explaining mechanisms, interpreting findings, and choosing management rather than studying disease names alone.
What are the examination question count and scored/pretest split?
A verified initial-certification question total and scored-versus-pretest breakdown are not established by these sources. The 20 original questions in this guide are independent learning drills and do not represent an official examination length or predict passing.
ABP Pediatric Hematology-Oncology Content Outline · ASPHO: Certification in Pediatric Hematology/Oncology
What are the duration, delivery method, adaptivity, and item styles?
The outline illustrates a four-option, single-best-answer item. It does not establish the complete range of current item styles, examination duration, delivery arrangements, or whether initial certification uses adaptive testing. Current candidate instructions are needed for those logistical details.
ABP Pediatric Hematology-Oncology Content Outline · ASPHO: Certification in Pediatric Hematology/Oncology
How do initial certification, in-training assessment, and maintenance pathways differ?
The outline assigns the same domain weights to in-training and initial-certification examinations, but they serve different purposes. Its maintenance examination columns include combined hematology-oncology, hematology-focused, and oncology-focused distributions. ASPHO also describes MOCA-Peds as a maintenance assessment; its quarterly question structure must not be applied to initial certification.
ABP Pediatric Hematology-Oncology Content Outline · ASPHO: Certification in Pediatric Hematology/Oncology
Are a passing score, fee, or exact examination date verified here?
These sources do not establish a current initial-certification passing score, fee, or exact appointment date. ASPHO describes an approximately biennial schedule, generally in spring of odd-numbered years, but that description is not confirmation of a particular examination administration.
This guide addresses the American Board of Pediatrics physician subspecialty initial certification examination in Pediatric Hematology-Oncology. It is independent educational material, not an ABP publication or a general medical licensure examination.
Outline used: ABP Pediatric Hematology-Oncology Content Outline, effective April 1, 2019; initial-certification column. The ABP-authored outline was opened through ASPHO, whose current certification page continues to identify it as applicable. The workbook label maps to this physician subspecialty certification examination; the assigned slug is preserved. No separately dated 2026 outline was established.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Erythrocytes13%
1.What laboratory pattern identifies depleted iron stores?
Iron deficiency limits hemoglobin synthesis, eventually producing hypochromic, microcytic erythrocytes. A low ferritin strongly supports depleted stores, while transferrin saturation reflects iron available for erythropoiesis. Ferritin can rise with inflammation, so a normal result does not reliably exclude deficiency during illness. Interpret the CBC, iron studies, diet, and bleeding history together. Microcytosis alone identifies a pattern rather than its cause; thalassemia and inflammatory iron restriction remain competing explanations.
Apply it
A toddler with excessive cow's-milk intake has microcytosis and a clearly low ferritin. Connect the dietary history with depleted stores, begin appropriate iron replacement, and address the diet rather than treating the CBC result in isolation.
Common pitfall: A normal ferritin during inflammation can falsely reassure. Conversely, microcytosis without evidence of depleted stores should not automatically trigger a diagnosis of nutritional iron deficiency.
2.Why does recurrent iron deficiency require a search for its cause?
Iron replacement restores a deficit but does not explain why it developed. Pediatric causes include inadequate intake, increased requirements, impaired absorption, and chronic blood loss. An expected hematologic response supports iron-responsive anemia; an inadequate response requires checking adherence, administration, ongoing loss, absorption, and the diagnosis. Recurrent deficiency after apparent correction particularly suggests that the original cause persists. In adolescents, menstrual and gastrointestinal histories can be more informative than repeating an isolated serum iron measurement.
Apply it
An adolescent's anemia improves with iron but returns several months later. A history of prolonged heavy menstrual bleeding redirects the evaluation toward continuing blood loss and a possible bleeding disorder while iron stores are replenished.
Common pitfall: Repeatedly prescribing iron without identifying ongoing loss can temporarily improve hemoglobin while leaving the cause untreated. Apparent treatment failure also requires an adherence assessment before rare diagnoses.
3.How does the reticulocyte response distinguish hemolysis from impaired production?
Reticulocytes indicate marrow erythrocyte output and must be interpreted relative to the degree of anemia. In hereditary spherocytosis, shortened red-cell survival usually stimulates reticulocytosis, often accompanied by indirect hyperbilirubinemia and splenomegaly. A low or inappropriately normal reticulocyte response during severe anemia suggests inadequate production or a superimposed production defect. The reticulocyte percentage alone can be misleading because the circulating erythrocyte denominator falls in anemia; absolute output and clinical context are more informative.
Apply it
A child with established hereditary spherocytosis develops a rapid hemoglobin decline. Instead of assuming accelerated destruction, compare the absolute reticulocyte count with baseline; a marked fall suggests that marrow compensation has temporarily failed.
Common pitfall: Hemolytic disease does not guarantee reticulocytosis during every deterioration. A production crisis can coexist with chronic shortened red-cell survival and produce unusually severe anemia.
4.What causes red-cell destruction in hereditary spherocytosis?
Defects in red-cell membrane-associated proteins destabilize the membrane and reduce the surface-area-to-volume ratio. The resulting spherocytes deform poorly and undergo preferential splenic destruction, causing extravascular hemolysis. EPB42-related disease involves protein 4.2 and is typically autosomal recessive; hereditary spherocytosis as a broader category has several genetic causes and inheritance patterns. Spherocytes support the diagnosis but also occur in immune hemolysis, so morphology must be integrated with family history, antiglobulin testing, and specialized membrane evaluation.
Apply it
A child has chronic jaundice, splenomegaly, reticulocytosis, and spherocytes with a negative direct antiglobulin test. This combination favors a membrane disorder over antibody-mediated hemolysis and supports confirmatory evaluation for hereditary spherocytosis.
Common pitfall: Do not assume that every spherocyte proves hereditary spherocytosis or that every affected family follows dominant inheritance. Protein 4.2 deficiency illustrates an important recessive subtype.
5.Which findings distinguish an aplastic crisis in hereditary spherocytosis?
Parvovirus B19 can transiently suppress erythroid production. Because hereditary spherocytosis shortens erythrocyte survival, even a brief interruption in production can cause a profound hemoglobin decline. The discriminating finding is reticulocytopenia, contrasting with the usual compensatory reticulocytosis of chronic hemolysis. Assess symptoms and hemodynamic status to determine supportive transfusion needs. Increased destruction may also lower hemoglobin, but it generally preserves or increases marrow compensation when erythropoiesis remains intact and nutrient supply is adequate.
Apply it
After a febrile illness, a child with hereditary spherocytosis becomes pale and tachycardic. Hemoglobin falls substantially while reticulocytes nearly disappear. Recognize an erythroid production crisis and assess the need for urgent supportive transfusion.
Common pitfall: A falling hemoglobin should not automatically be labeled a hemolytic crisis. The reticulocyte direction distinguishes suppressed production from an appropriately compensating marrow in this setting.
6.When does abnormal transcranial Doppler screening change sickle cell management?
Screen children with HbSS or HbSβ0 thalassemia annually from ages 2 through 16 years. Nonimaging TCD measures the time-averaged mean of maximum velocities, or TAMMV, in the distal internal carotid or proximal middle cerebral artery. Treatment criteria are two measurements at or above 200 cm/s or one above 220 cm/s. Imaging TCD uses lower criteria: two time-averaged maximum measurements at or above 185 cm/s or one above 205 cm/s. These are not peak systolic velocities. Confirmed abnormal results support transfusions every 3 to 4 weeks for at least one year where feasible, maintaining maximum HbS below 30% and hemoglobin above 9 g/dL. The [DISPLACE comparison with ASH recommendations](https://ashpublications.org/bloodadvances/article/8/13/3444/515907/DISPLACE-study-shows-poor-quality-of-transcranial) details the technique-specific thresholds.
Apply it
An asymptomatic 8-year-old with HbSS has nonimaging TAMMV measurements of 207 and 211 cm/s on separate studies. These meet repeated abnormal criteria and support regular transfusion for primary stroke prevention. A single nonimaging value of 223 cm/s also meets the single-study criterion.
Common pitfall: Do not transfer thresholds between imaging and nonimaging techniques or substitute peak systolic velocity for the required time-averaged parameter. A normal neurologic examination does not remove the risk.
ASH Sickle Cell Disease Cerebrovascular Guidelines Snapshot · ASH: Managing Cerebrovascular Disease in Sickle Cell Disease
7.Why can brain MRI be indicated despite normal sickle cell Doppler screening?
Transcranial Doppler screening and brain MRI address different cerebrovascular problems. Doppler velocities identify elevated overt-stroke risk, whereas MRI can reveal silent cerebral infarction without a corresponding focal neurologic history or examination finding. ASH recommends at least one screening MRI in early school-age children with HbSS or HbSβ0 thalassemia when it can be performed without sedation. Detection prompts neurologic assessment, cognitive and educational evaluation, and discussion of strategies to reduce further cerebral injury.
Apply it
A school-age child with HbSS has normal Doppler screening but worsening classroom performance. Explain that normal velocities do not exclude silent infarction, and consider the recommended MRI assessment alongside evaluation of other educational and medical contributors.
Common pitfall: Silent infarction is not synonymous with an incidental harmless finding. Conversely, an MRI lesion requires appropriate clinical interpretation rather than automatic classification as a prior overt stroke.
ASH: Managing Cerebrovascular Disease in Sickle Cell Disease
8.How should acute focal neurologic symptoms in sickle cell disease be approached?
A new focal deficit or transient ischemic attack requires urgent neurologic assessment, imaging, and transfusion planning in parallel, aiming to begin transfusion within two hours of presentation. Exchange transfusion is preferred. If exchange cannot begin within two hours and hemoglobin is 8.5 g/dL or lower, simple transfusion toward 10 g/dL can bridge to exchange. Above 8.5 g/dL, exchange reduces HbS without the excessive viscosity increase that simple transfusion could produce. Postexchange targets commonly include HbS of 15% to 20% and hemoglobin around 10 g/dL; the ASH teaching guidance describes a postapheresis hemoglobin range of 10 to 12 g/dL.
Apply it
A child with HbSS develops sudden unilateral weakness and has hemoglobin of 7 g/dL. If exchange is several hours away, begin simple transfusion toward 10 g/dL while arranging exchange and urgent imaging. With a starting hemoglobin of 9.5 g/dL, prioritize exchange to limit hyperviscosity.
Common pitfall: Transient resolution does not make the event benign. Avoid delaying transfusion for completion of every diagnostic study or pursuing a high hemoglobin while a substantial HbS fraction remains.
ASH: Managing Cerebrovascular Disease in Sickle Cell Disease
Leukocytes4%
9.What does dihydrorhodamine testing measure in chronic granulomatous disease?
Chronic granulomatous disease results from impaired phagocyte NADPH oxidase activity, reducing the respiratory burst needed for effective intracellular microbial killing. Stimulated dihydrorhodamine testing assesses neutrophil oxidative activity by flow cytometry. Recurrent deep infections, invasive fungal disease, and granulomatous inflammation can suggest the diagnosis despite a normal neutrophil count. Molecular characterization defines the genetic cause. In heterozygous females with X-linked disease, X-inactivation can produce normal and abnormal oxidative-burst populations; markedly skewed inactivation can confer clinical risk.
Apply it
A child has recurrent hepatic abscesses and invasive Aspergillus infection despite normal neutrophil numbers. Request an oxidative-burst assay. A carrier relative with two distinct functional populations also needs assessment of infection and inflammatory symptoms.
Common pitfall: Normal cell numbers do not establish normal function. Two oxidative-burst populations can reflect carrier mosaicism, and carrier status does not guarantee absence of clinical disease.
10.How does leukocyte adhesion deficiency differ from an oxidative-burst defect?
In leukocyte adhesion deficiency type 1, deficient CD18-containing β2 integrins impair firm adhesion and neutrophil migration across vascular endothelium. Circulating neutrophils can be markedly elevated while infected tissues receive too few cells. Delayed umbilical-cord separation, recurrent soft-tissue infection, poor wound healing, and scant pus are characteristic cues. Flow cytometric analysis of CD18 and associated CD11 markers evaluates this adhesion defect. In contrast, chronic granulomatous disease impairs oxidative killing after phagocytosis. The [leukocyte emigration report](https://pubmed.ncbi.nlm.nih.gov/8500276/) explains the CD11/CD18 mechanism.
Apply it
An infant has omphalitis, delayed cord separation, poor wound healing, and persistent neutrophilia. Investigate adhesion-marker expression rather than interpreting the high neutrophil count as evidence of adequate tissue defense.
Common pitfall: Neutrophilia can coexist with profound phagocyte dysfunction. Adhesion-marker analysis and oxidative-burst testing assess different steps in host defense.
Platelets7%
11.How do Glanzmann thrombasthenia and Bernard-Soulier syndrome produce different platelet-test patterns?
Glanzmann thrombasthenia impairs platelet αIIbβ3, or GPIIb/IIIa, function and fibrinogen-mediated aggregation. Platelet number and size are usually normal; aggregation is defective with several physiological agonists, while ristocetin-induced agglutination is preserved. Bernard-Soulier syndrome impairs the GPIb-IX-V receptor for von Willebrand factor, causing defective adhesion, giant platelets, thrombocytopenia, and reduced ristocetin-induced agglutination. Flow cytometry can demonstrate the corresponding receptor abnormality. These distinctions are described in the [ASH review of inherited platelet disorders](https://ashpublications.org/hematology/article/2013/1/268/20801/Inherited-platelet-disorders-including-Glanzmann).
Apply it
A child with lifelong mucosal bleeding has normal platelet size and count, absent aggregation with multiple agonists, and preserved ristocetin response. This favors Glanzmann thrombasthenia. Giant platelets with thrombocytopenia and impaired ristocetin response instead favor Bernard-Soulier syndrome.
Common pitfall: Mucosal bleeding does not establish ITP. Lifelong symptoms, family history, platelet morphology, aggregation studies, and receptor expression distinguish inherited function disorders from immune destruction.
12.When is observation appropriate for newly diagnosed childhood immune thrombocytopenia?
Typical childhood ITP presents with isolated thrombocytopenia in an otherwise well child; review the smear and reconsider the diagnosis with blasts, unexplained additional cytopenias, bone pain, or organomegaly. ASH recommends observation for newly diagnosed children with no bleeding or only minor skin bleeding. Bleeding severity, quality of life, diagnostic confidence, and follow-up reliability matter more than an isolated platelet threshold. Outpatient management can be appropriate even with very low counts. Families need bleeding precautions, return instructions, and hematology follow-up generally within 24 to 72 hours.
Apply it
A child has platelets of 9 × 10^9/L, scattered bruises, no mucosal bleeding, an otherwise reassuring CBC and smear, and reliable caregivers. Observation with prompt follow-up can be appropriate; the count alone does not require admission or intravenous immunoglobulin.
Common pitfall: Observation requires education and reassessment. It is less suitable with diagnostic uncertainty, significant bleeding, unreliable follow-up, or findings suggesting marrow or systemic disease.
13.How does nonmajor mucosal bleeding alter initial immune thrombocytopenia treatment?
Children with newly diagnosed ITP and non-life-threatening mucosal bleeding or impaired health-related quality of life may benefit from treatment. ASH recommends corticosteroid courses of seven days or less rather than longer courses and generally favors corticosteroids over intravenous immunoglobulin for this presentation. A suggested prednisone regimen is 2 to 4 mg/kg/day, maximum 120 mg/day, for five to seven days. Monitor blood pressure, glucose when indicated, sleep, mood, and gastrointestinal symptoms. Selection also considers the required speed of response, contraindications, and family circumstances.
Apply it
A stable child has recurrent troublesome epistaxis without major blood loss. After assessing severity and contraindications, consider five to seven days of prednisone rather than extending treatment for several weeks to normalize the platelet count.
Common pitfall: These recommendations concern nonmajor bleeding. Critical hemorrhage requires emergency treatment; it should not be managed by simply applying this outpatient steroid regimen.
14.Which second-line options matter when childhood immune thrombocytopenia remains symptomatic?
For children with persistent symptoms or reduced quality of life despite first-line treatment, ASH favors thrombopoietin-receptor agonists over rituximab or splenectomy in the relevant second-line comparisons. These agents increase platelet production rather than directly removing circulating antiplatelet antibodies. Selection depends on treatment burden, adverse effects, access, family preferences, and the possibility of spontaneous improvement. A persistently low count without clinically important bleeding or impaired quality of life does not automatically justify escalation.
Apply it
A child with ongoing immune thrombocytopenia has frequent mucosal bleeding despite first-line therapy. Discuss a thrombopoietin-receptor agonist and its monitoring requirements, while considering family preferences and avoiding an automatic move to irreversible splenectomy solely because thrombocytopenia persists.
Common pitfall: Persistence and treatment failure are not interchangeable. Escalation should address meaningful bleeding or quality-of-life burden, rather than attempting to normalize every platelet count.
ASH: Management of Immune Thrombocytopenia Pocket Guide · ASH Clinical Practice Guidelines on Immune Thrombocytopenia
Hemostasis/Thrombosis10%
15.How are hemophilia A and hemophilia B distinguished?
Hemophilia A reflects factor VIII deficiency, whereas hemophilia B reflects factor IX deficiency. Both can cause deep tissue bleeding and hemarthroses, so the bleeding phenotype alone does not distinguish them. A prolonged activated partial thromboplastin time can suggest an intrinsic-pathway abnormality, but factor-specific activity assays establish the deficient factor and severity. Mild hemophilia may not prolong every screening assay, making targeted testing important when the personal or family bleeding history is convincing.
Apply it
A boy with recurrent hemarthroses has normal platelets and a prolonged activated partial thromboplastin time. Measure factor VIII and IX activities to identify the deficiency rather than choosing the hemophilia subtype from the joint bleeding pattern alone.
Common pitfall: A screening clotting time is not a factor assay. A normal result also does not reliably exclude mild hemophilia when the history warrants specific testing.
16.Why is neonatal factor IX activity interpreted differently from factor VIII activity?
Factor IX activity is physiologically lower in newborns and rises with maturation, whereas factor VIII is generally at adult-range levels at birth. Consequently, severe hemophilia B may be identifiable early, but a modestly reduced neonatal factor IX level may require later reassessment before mild disease is confirmed. Family history and molecular testing can clarify risk. Developmental hemostasis means an adult reference interval cannot be applied mechanically to every neonatal coagulation result.
Apply it
A newborn with a family history of hemophilia B has factor IX activity that is mildly reduced relative to an adult range. Interpret the result using age-specific expectations and arrange appropriate confirmation rather than immediately assigning mild hemophilia.
Common pitfall: Physiologically low neonatal factor IX does not make all low results harmless. Severe deficiency, bleeding, and a known familial variant still demand prompt diagnostic attention.
17.Which von Willebrand factor levels support type 1 von Willebrand disease?
The ASH-led guideline supports a von Willebrand factor level below 0.30 IU/mL regardless of bleeding, or below 0.50 IU/mL in a patient with abnormal bleeding, to confirm type 1 VWD. The relevant level may be antigen or platelet-dependent activity. Test at baseline health when feasible because bleeding, trauma, inflammation, and other stress can elevate VWF and conceal deficiency. Repeat a normal panel obtained during illness when it conflicts with a convincing bleeding history. Discordant activity and antigen require assessment for qualitative disease.
Apply it
An adolescent with substantial menstrual and dental bleeding has baseline VWF activity of 0.42 IU/mL. This is diagnostically meaningful in the bleeding context. A normal panel obtained during an acute infection would warrant reassessment after recovery.
Common pitfall: The below-0.50 criterion is linked to abnormal bleeding. A single normal result during physiologic stress does not exclude disease, and an isolated low value does not establish every VWD subtype.
18.How do unfractionated and low-molecular-weight heparin differ in pediatric anticoagulation?
Both heparins enhance antithrombin-mediated inhibition of coagulation; unfractionated heparin inhibits thrombin and factor Xa, while low-molecular-weight heparin has proportionally greater anti-Xa activity. Intravenous unfractionated heparin has a short half-life and can be rapidly stopped and reversed with protamine, making it useful when bleeding risk, procedures, or severe renal dysfunction favor rapid control. Low-molecular-weight heparin permits subcutaneous treatment but requires attention to renal clearance; protamine reverses its anti-Xa effect incompletely. Pediatric monitoring uses agent-appropriate assays and dose adjustment. See the [ASH discussion of pediatric VTE treatment](https://ashpublications.org/blood/article/135/5/335/430071/Treatment-of-venous-thromboembolism-in-pediatric).
Apply it
A child with symptomatic thrombosis has severe renal impairment and may need an urgent procedure. Unfractionated heparin's short duration and reversibility can be advantageous. A stable child receiving outpatient low-molecular-weight heparin instead needs planned injections and appropriately timed anti-Xa monitoring.
Common pitfall: An aPTT is not a reliable measure of low-molecular-weight heparin effect. Anticoagulation limits propagation while endogenous fibrinolysis acts; it does not directly dissolve the clot.
19.How does a low von Willebrand activity-to-antigen ratio suggest qualitative disease?
Von Willebrand factor antigen estimates protein quantity, whereas platelet-dependent activity evaluates function. A disproportionately low activity relative to antigen suggests a qualitative defect rather than a proportional quantitative reduction. The diagnostic guideline favors an activity-to-antigen ratio below 0.7 when evaluating suspected type 2A, 2B, or 2M disease after an abnormal initial screen. Further subtype testing is needed because this ratio identifies a pattern, not a complete molecular or functional subtype diagnosis.
Apply it
A patient with mucosal bleeding has activity of 0.24 IU/mL and antigen of 0.60 IU/mL. The ratio is 0.40, directing further evaluation toward qualitative von Willebrand disease rather than assuming uncomplicated proportional type 1 deficiency.
Common pitfall: A low ratio does not distinguish all type 2 subtypes. Additional testing is necessary before making subtype-specific treatment decisions or assuming a particular molecular defect.
20.Why can thrombosis occur during acute lymphoblastic leukemia therapy?
Thrombosis during acute lymphoblastic leukemia treatment reflects interacting disease and treatment risks. Asparaginase disrupts hepatic protein synthesis, including natural anticoagulants, while central venous catheters, glucocorticoids, and illness add risk. Cerebral venous thrombosis may present with headache, seizures, or focal deficits rather than limb swelling. New symptoms require targeted evaluation instead of being attributed automatically to chemotherapy discomfort. The presence of thrombocytopenia does not eliminate the possibility of a clinically important thrombotic event.
Apply it
A teenager receiving asparaginase and glucocorticoids develops severe headache and a seizure. Include cerebral venous thrombosis in the urgent differential and obtain appropriate vascular imaging rather than attributing the episode solely to medication-related nausea or fatigue.
Common pitfall: Cancer-associated bleeding and thrombosis can coexist. A low platelet count or recent lumbar puncture does not, by itself, exclude a cerebral venous clot.
Bone Marrow Failure5%
21.What establishes the cellular defect in Fanconi anemia, and what does transplantation correct?
Fanconi anemia is a DNA-repair disorder with cellular hypersensitivity to interstrand cross-linking agents. Increased chromosome breakage after diepoxybutane or mitomycin C exposure supports the diagnosis; molecular testing identifies the genetic cause. Congenital anomalies may accompany progressive cytopenias but are not required. The repair defect increases toxicity from genotoxic therapy and affects conditioning selection. HSCT can restore hematopoiesis but does not correct the constitutional defect in other tissues, so solid-tumor susceptibility and syndrome-specific surveillance persist after engraftment.
Apply it
A child has progressive pancytopenia, short stature, and a thumb abnormality. Obtain inherited marrow-failure testing before treating the presentation as acquired aplastic anemia. If transplantation later normalizes counts, continue surveillance for nonhematopoietic complications.
Common pitfall: Absence of congenital anomalies does not exclude Fanconi anemia. Normal counts after transplantation do not establish a complete cure of the inherited multisystem disorder.
22.Why can blood chromosome-breakage testing miss mosaic Fanconi anemia?
Somatic reversion can restore DNA-repair function in a subset of hematopoietic cells, creating mosaicism in Fanconi anemia. Peripheral-blood chromosome-breakage results may therefore be equivocal or unexpectedly normal despite a convincing clinical phenotype. Testing a nonhematopoietic tissue, commonly cultured skin fibroblasts, can reveal the underlying cross-linker sensitivity. This distinction matters because hematopoietic improvement does not demonstrate correction of the constitutional defect in other tissues or eliminate associated malignancy and treatment-toxicity concerns.
Apply it
A child with characteristic anomalies and unexplained marrow failure has an unexpectedly normal blood breakage study. Discuss fibroblast testing because hematopoietic mosaicism may conceal the constitutional defect in a blood-only assessment despite the concerning phenotype.
Common pitfall: A reassuring blood result should not automatically end a strongly indicated evaluation. Mosaic hematopoiesis also does not imply that every organ has undergone genetic correction.
23.How is acquired aplastic anemia distinguished from other causes of pancytopenia?
Acquired aplastic anemia combines cytopenias with markedly hypocellular marrow lacking a malignant infiltrate; immune-mediated stem-cell injury is a major mechanism. Aspirate, biopsy, morphology, cytogenetics, and inherited-disease evaluation help exclude competing diagnoses. With the requisite hypocellular marrow and diagnostic exclusions, the [2026 ASH pocket guide](https://www.hematology.org/-/media/hematology/files/clinicians/guidelines/ash-cpg-aplastic-anemia-pocket-guide-6-panel-0320-nocropmarks.pdf) defines severe disease by at least two of three peripheral abnormalities: neutrophils below 500/µL, absolute reticulocytes below 60,000/µL, and platelets below 20,000/µL. All three are not required. Very severe disease meets severe criteria and additionally has neutrophils below 200/µL. Severity, age, donor availability, and inherited-disease assessment guide transplantation versus immunosuppressive treatment.
Apply it
A child has markedly hypocellular marrow without excess blasts, neutrophils of 350/µL, platelets of 15,000/µL, and absolute reticulocytes of 75,000/µL. After excluding competing diagnoses, the neutrophil and platelet abnormalities satisfy the two-of-three rule for severe disease despite reticulocytes above the cutoff. Neutrophils of 150/µL with the same other findings would establish very severe disease.
Common pitfall: Hypocellularity alone does not prove an acquired immune cause. Do not require all three peripheral thresholds, substitute reticulocyte percentage for absolute count, or classify very severe disease without first satisfying severe criteria.
ABP Pediatric Hematology-Oncology Content Outline · NCI: Childhood Acute Myeloid Leukemia Treatment
Transfusion Medicine5%
24.How do irradiation, leukoreduction, and CMV-seronegative selection address different transfusion hazards?
Irradiation prevents transfusion-associated graft-versus-host disease by disabling viable donor T-lymphocyte proliferation. Defined indications include relevant transplant settings and cellular donations from relatives. Leukoreduction removes most donor leukocytes, reducing febrile nonhemolytic reactions and transmission of leukocyte-associated CMV, but does not reliably prevent donor T-cell proliferation. CMV-seronegative selection instead uses donor antibody status; neither CMV strategy guarantees zero transmission, and recipient-specific policy determines the required approach. Irradiation does not prevent antibody-mediated hemolysis or allergic reactions and does not sterilize the component. These processing and donor-selection decisions must be assessed separately.
Apply it
A transplant candidate needs red cells. Confirm irradiation when indicated even if the unit is leukoreduced, then check the required CMV-risk strategy separately. A CMV-seronegative label does not establish protection against donor lymphocyte proliferation.
Common pitfall: Leukoreduced does not mean free of viable donor T cells. CMV-seronegative does not mean pathogen-free, and neither label replaces irradiation when indicated.
Canadian Blood Services: Irradiated, Washed and CMV Seronegative Blood Components
25.When does washing a blood component address the relevant transfusion risk?
Washing removes most residual plasma proteins and other supernatant constituents from cellular blood components. It can help selected patients with recurrent severe allergic reactions or specific plasma-protein-related concerns. Washing does not provide the donor T-cell inactivation required to prevent transfusion-associated graft-versus-host disease and does not replace compatibility testing. Product preparation can reduce available cells and alter storage constraints, so the indication should match the reaction mechanism rather than treating washing as a universal safety upgrade.
Apply it
A child has repeated severe allergic reactions to red-cell transfusions despite an appropriate evaluation and preventive plan. Discuss washed components to reduce plasma exposure, while separately checking whether irradiation and other recipient-specific processing requirements remain indicated.
Common pitfall: Washing and irradiation solve different problems. A washed component is not automatically suitable for a patient who specifically requires prevention of donor lymphocyte proliferation.
Canadian Blood Services: Irradiated, Washed and CMV Seronegative Blood Components
26.Which acute transfusion findings require immediate evaluation for hemolysis?
Fever with pain, hypotension, hemoglobinuria, or oliguria during red-cell transfusion suggests an acute hemolytic reaction, including ABO incompatibility. Stop the transfusion immediately, notify the blood bank, and support circulation with close monitoring and appropriate hydration. Repeat compatibility assessment and DAT, together with hemolysis and renal studies, investigate the mechanism. Bacterial contamination can also cause fever and hypotension; obtain recipient and component cultures and give empiric antibiotics when suspected. The [Canadian Blood Services transfusion-reaction guideline](https://profedu.blood.ca/en/transfusion/clinical-guide/transfusion-reactions) describes these responses.
Apply it
During transfusion, a child develops fever, back pain, red urine, and hypotension. Stop immediately and initiate urgent assessment and supportive care; do not wait for DAT or repeat crossmatch results.
Common pitfall: Do not label fever as a benign febrile nonhemolytic reaction before excluding dangerous causes, particularly when hypotension or hemoglobinuria is present.
General Oncology Issues14%
27.What biochemical pattern signals tumor lysis syndrome?
Rapid tumor-cell breakdown releases potassium, phosphate, and nucleic acids. Purine metabolism raises uric acid, while phosphate can bind calcium and promote calcium-phosphate deposition. The characteristic pattern is hyperkalemia, hyperphosphatemia, hyperuricemia, and secondary hypocalcemia, with potential acute kidney injury, arrhythmia, or seizure. Tumor lysis may occur spontaneously or after treatment. Risk rises with highly proliferative, treatment-sensitive disease, large tumor burden, and impaired renal clearance, making pre-treatment assessment and serial monitoring essential.
Apply it
Soon after leukemia treatment begins, a child develops rising potassium, phosphate, uric acid, and creatinine with falling calcium. Recognize a coordinated lysis syndrome and escalate monitoring and treatment rather than managing each result as an unrelated abnormality.
Common pitfall: Tumor lysis is not limited to hyperuricemia and can precede chemotherapy. A reassuring initial uric acid does not eliminate the need to assess other electrolytes and renal function.
28.How do allopurinol and rasburicase differ in tumor lysis prevention?
Allopurinol inhibits xanthine oxidase, reducing new uric acid formation without removing urate already present. Rasburicase converts existing uric acid to more soluble allantoin. Urate oxidation also produces hydrogen peroxide, creating a risk of hemolysis and methemoglobinemia when antioxidant defenses are impaired. Known G6PD deficiency is a contraindication: rasburicase must not be administered. Assess G6PD status before treatment and screen patients at increased risk, including relevant ancestry or family history. Stop rasburicase permanently if hemolysis or methemoglobinemia develops. Uric acid specimens require chilled handling because the enzyme continues degrading urate outside the body.
Apply it
A child with bulky, treatment-sensitive cancer has marked hyperuricemia and confirmed G6PD deficiency. Avoid rasburicase and use an alternative urate-management strategy with hydration, close biochemical monitoring, and renal support when indicated.
Common pitfall: Monitoring after administration does not make rasburicase acceptable in known G6PD deficiency. Neither urate-lowering agent directly corrects hyperkalemia or hyperphosphatemia.
eviQ: Prevention of Tumour Lysis Syndrome · 103946s5103lbl.pdf
29.Which empiric antibiotic strategy fits high-risk pediatric fever and neutropenia?
High-risk pediatric fever and neutropenia requires prompt empiric antibacterial therapy with activity against Pseudomonas and other serious bacterial pathogens. The pediatric guideline supports monotherapy with an appropriate antipseudomonal beta-lactam, a fourth-generation cephalosporin, or a carbapenem according to local susceptibility and patient factors. Additional Gram-negative or glycopeptide coverage is reserved for clinical instability, suspected resistant infection, or relevant local resistance. Routine combination therapy for every stable child adds toxicity without being the default recommended strategy.
Apply it
A child receiving intensive leukemia therapy presents with fever and profound neutropenia but stable perfusion. Obtain indicated cultures promptly and start an appropriate antipseudomonal regimen; add broader coverage when clinical findings or resistance risks justify it.
Common pitfall: A well appearance does not justify delaying antibiotics in high-risk fever and neutropenia. Conversely, automatic vancomycin for every fever ignores the guideline's indications for additional coverage.
30.When is chest radiography useful in pediatric fever and neutropenia?
The pediatric fever and neutropenia guideline recommends chest radiography when respiratory signs or symptoms are present, rather than routinely for every febrile neutropenic child. Cough, tachypnea, hypoxemia, or abnormal pulmonary findings provide a clinical reason to look for a respiratory source. A stable child without respiratory features has a low expected yield from routine radiography. Imaging decisions should answer a focused clinical question and should not delay the initial cultures, assessment, or empiric antibacterial treatment.
Apply it
Two neutropenic children develop fever. One has new hypoxemia and cough; the other has a normal respiratory history and examination. Obtain chest radiography for the symptomatic child rather than ordering it automatically for both presentations.
Common pitfall: Avoiding routine radiography in an asymptomatic child does not mean avoiding pulmonary evaluation when new respiratory findings develop. Reassess imaging needs as the clinical picture changes.
31.How should persistent fever change management in a neutropenic child?
Persistent fever alone does not require broader antibacterial therapy in a clinically stable child. At 96 hours or more of fever with neutropenia despite appropriate broad-spectrum antibiotics, assess invasive-fungal-disease risk. High-risk groups include AML, high-risk or relapsed ALL, prolonged neutropenia, high-dose corticosteroids, and specified allogeneic-HCT settings with poor T-cell recovery or substantial immunosuppression. Perform lung CT in high-risk patients and initiate empiric caspofungin or liposomal amphotericin B unless a preemptive strategy is selected. The conditional preemptive option concerns selected non-HCT high-risk patients not receiving antimold prophylaxis: defer empiric therapy while evaluating, then treat when findings suggest invasive fungal disease.
Apply it
A child receiving AML therapy has 100 hours of persistent fever and profound neutropenia despite appropriate antibiotics. Obtain lung CT and undertake fungal evaluation while initiating the appropriate empiric antifungal pathway. A carefully selected non-HCT patient without antimold prophylaxis may follow the conditional preemptive pathway.
Common pitfall: Fever persistence and clinical deterioration are different triggers. Instability requires immediate antibacterial reassessment and escalation; a preemptive antifungal strategy requires active evaluation rather than waiting without surveillance.
32.Why does anthracycline exposure require long-term cardiac follow-up?
Anthracyclines can cause progressive myocardial injury and later cardiomyopathy, including dysfunction that appears years after treatment. Risk depends on cumulative exposure and interacting factors such as cardiac radiation exposure, age, and other cardiovascular risks. A normal examination at treatment completion does not exclude future disease. Survivorship care should reconstruct the treatment history and use exposure-based cardiac surveillance, while addressing modifiable risks. New exercise intolerance, dyspnea, or edema warrants assessment rather than attribution solely to deconditioning.
Apply it
A leukemia survivor with prior anthracycline treatment feels well and asks whether follow-up can stop. Explain that delayed myocardial dysfunction can occur and use the treatment summary to determine continued cardiac surveillance and cardiovascular risk counseling.
Common pitfall: Current absence of symptoms does not establish absence of late cardiotoxicity. Surveillance should reflect cumulative treatment exposures rather than the original cancer diagnosis alone.
33.Which treatment exposures make fertility counseling time-sensitive?
Alkylating chemotherapy, gonadal radiation, and some transplant regimens can impair reproductive function. Risk varies with cumulative exposure, gonadal dose, age, sex, and baseline reserve. Counseling is most useful before potentially gonadotoxic treatment begins, when established preservation options may still be feasible. Pubertal status influences available methods but does not eliminate the need for discussion. Continued menstruation or apparently normal pubertal development after therapy does not prove preserved long-term fertility or adequate reproductive reserve.
Apply it
An adolescent is about to start an alkylator-intensive regimen. Arrange timely fertility counseling before treatment, discussing feasible preservation options and the urgency of cancer therapy rather than postponing the conversation until survivorship clinic.
Common pitfall: Normal puberty and preserved fertility are different outcomes. Avoid promising fertility on the basis of menstruation, testosterone production, or the absence of immediate gonadal symptoms.
34.How does radiation exposure shape survivorship surveillance?
Radiation late effects depend on the organs exposed, dose, field, age at treatment, and accompanying therapies. Potential consequences include endocrine dysfunction, impaired growth, vascular injury, and subsequent neoplasms. Surveillance should therefore begin with a treatment summary identifying anatomical exposures rather than a generic schedule based only on cancer type. Some risks emerge after long latency, so transition to adult care must preserve exposure information. A new mass in a prior treatment field requires evaluation rather than automatic attribution to benign scarring.
Apply it
A survivor transfers care with a history of chest and neck irradiation. Obtain the radiation fields and doses so follow-up can address relevant thyroid, cardiovascular, and subsequent-cancer risks rather than relying on a nonspecific annual examination.
Common pitfall: Radiation exposure is not a single uniform risk category. A surveillance plan must identify which tissues received treatment and consider latency and combined treatment exposures.
Hematologic Malignancies11%
35.Why does measurable residual disease refine acute lymphoblastic leukemia risk?
Measurable residual disease detects leukemic cells below the sensitivity of routine morphology using validated flow-cytometric or molecular methods. It measures treatment response and provides prognostic information beyond the initial disease burden. Interpretation depends on assay sensitivity, specimen quality, treatment time point, and protocol-specific thresholds. Morphologic remission can therefore coexist with clinically important residual leukemia. Conversely, an undetectable result means disease is below the assay's detection limit, not that every leukemic cell has certainly been eradicated.
Apply it
A child's marrow meets morphologic remission criteria after induction, but a validated assay detects residual leukemia. Incorporate the result into protocol-specific risk assessment rather than describing the marrow as biologically equivalent to an MRD-negative remission.
Common pitfall: MRD results from different time points or assays are not automatically interchangeable. Undetectable disease also should not be translated into a guarantee of cure.
36.Why does acute lymphoblastic leukemia require central nervous system-directed therapy?
The central nervous system is a sanctuary site where leukemia can persist despite apparent marrow response because drug penetration and local disease biology differ from those in blood and marrow. CNS-directed therapy is therefore part of ALL treatment even without overt CNS leukemia at diagnosis. The approach combines protocol-defined intrathecal and systemic therapy, with radiation reserved for selected circumstances. A negative diagnostic cerebrospinal-fluid examination does not eliminate the need for preventive CNS-directed treatment.
Apply it
Parents ask why their child needs intrathecal therapy when the initial cerebrospinal fluid was negative. Explain that treatment addresses the risk of occult sanctuary-site disease and CNS relapse, rather than treating only cells visible in the initial specimen.
Common pitfall: Marrow remission does not establish sanctuary-site clearance. Conversely, recognition of CNS risk does not mean every child with ALL requires cranial irradiation.
37.Which presenting features contribute to B-cell acute lymphoblastic leukemia risk classification?
Age and presenting leukocyte count form an initial clinical risk framework for childhood B-cell ALL. The traditional NCI standard-risk group includes children aged 1 to younger than 10 years with a presenting leukocyte count below 50,000/µL. Final treatment assignment also incorporates genetics, extramedullary disease, and response measures such as MRD. Thus, favorable presenting clinical features cannot override an adverse molecular finding or inadequate treatment response, and the initial category is not a complete individualized prognosis.
Apply it
A 6-year-old with B-cell ALL presents with leukocytes of 18,000/µL but has persistent MRD after induction. Recognize the favorable initial clinical category while incorporating the unfavorable response into the treatment protocol's final risk assignment.
Common pitfall: The presenting leukocyte count is not the same as residual disease after treatment. Do not let an initial standard-risk label conceal later evidence of resistant leukemia.
38.How do lineage and molecular findings distinguish major childhood non-Hodgkin lymphomas?
Burkitt lymphoma is a mature B-cell neoplasm associated with MYC rearrangement, usually t(8;14) involving the immunoglobulin heavy-chain locus. Its rapid proliferation and frequent abdominal presentation make tumor lysis assessment urgent. T-lymphoblastic lymphoma involves immature T-lineage cells and commonly presents with a mediastinal mass; its treatment follows a prolonged ALL-like approach rather than the shorter intensive mature B-cell regimens. Morphology, coordinated immunophenotyping, genetics, and disease distribution establish the diagnosis. See [NCI Childhood Non-Hodgkin Lymphoma Treatment](https://www.cancer.gov/types/lymphoma/hp/child-nhl-treatment-pdq).
Apply it
A child has a rapidly enlarging abdominal mass with mature B-cell markers and an IGH-associated MYC rearrangement. This supports Burkitt lymphoma and an immediate tumor lysis plan. An anterior mediastinal mass with immature T-cell markers suggests a different lymphoma and treatment strategy.
Common pitfall: A mass location or one positive marker is insufficient for classification. A mediastinal mass also requires assessment of airway and cardiovascular compression before sedation or anesthesia.
ABP Pediatric Hematology-Oncology Content Outline · eviQ: Prevention of Tumour Lysis Syndrome
39.How do specific genetic alterations refine pediatric acute myeloid leukemia risk?
The t(8;21) rearrangement produces RUNX1::RUNX1T1, while inv(16), or t(16;16), produces CBFB::MYH11. These disrupt core-binding-factor transcriptional regulation and define AML groups with generally favorable outcomes under appropriate therapy. In contrast, NUP98::NSD1 is associated with poor response and adverse outcomes, particularly with co-occurring FLT3 internal tandem duplication. Genetics must still be integrated with MRD, other findings, and the treatment protocol; favorable classification does not make persistent disease irrelevant.
Apply it
One child has t(8;21), RUNX1::RUNX1T1, and rapid MRD clearance; another has NUP98::NSD1, FLT3-ITD, and persistent MRD. Their similar initial blast percentages conceal substantially different biological and response-based risks.
Common pitfall: Do not treat all AML fusions as equivalent or convert a favorable association into a guarantee of cure. A normal conventional karyotype can also miss a cryptic fusion.
40.How does transient abnormal myelopoiesis differ from myeloid leukemia of Down syndrome?
Transient abnormal myelopoiesis occurs in newborns with trisomy 21 and is associated with acquired GATA1 alterations. It often resolves spontaneously but can cause serious neonatal complications and predicts risk for later myeloid leukemia of Down syndrome. The later leukemia generally arises in early childhood and has distinct biology and treatment sensitivity. Spontaneous resolution of neonatal circulating blasts does not remove the need for follow-up, while the presence of neonatal blasts does not automatically justify conventional AML chemotherapy.
Apply it
A newborn with Down syndrome has circulating megakaryoblasts that subsequently disappear. Continue appropriate follow-up for later myeloid disease while assessing neonatal organ complications, rather than declaring the transient episode irrelevant once the blood count normalizes.
Common pitfall: Transient does not mean uniformly harmless. Severe neonatal disease can require intervention, but many cases differ fundamentally from persistent childhood AML in timing and management.
41.When does suspected acute promyelocytic leukemia require action before molecular confirmation?
Acute promyelocytic leukemia is associated with PML::RARA and a potentially fatal coagulopathy. Suspicious promyelocyte morphology with bleeding, thrombocytopenia, or coagulation abnormalities warrants urgent specialist management and prompt all-trans retinoic acid while confirmatory testing proceeds. Differentiation therapy addresses the disease mechanism, and intensive blood-product support addresses immediate hemorrhagic risk. Waiting for the final molecular report can expose the patient to preventable early bleeding. Ongoing care must also anticipate differentiation syndrome during treatment.
Apply it
A child has mucosal bleeding, low fibrinogen, and numerous abnormal promyelocytes. Treat the presentation as a hematologic emergency, arrange immediate APL-directed management and coagulation support, and confirm PML::RARA without delaying the initial response.
Common pitfall: APL requires a disease-specific emergency response. Early hemorrhage can be fatal before definitive therapy has time to control the leukemia.
Solid Tumors17%
42.Which biochemical findings support suspected neuroblastoma?
Neuroblastoma frequently produces catecholamine metabolites, so urinary homovanillic acid and vanillylmandelic acid can support evaluation of a compatible mass. These measurements complement imaging and pathological or accepted marrow-based diagnostic criteria; they are not a stand-alone population screening test or a substitute for complete characterization. A normal result does not exclude every neuroblastoma. The strongest interpretation combines age, tumor location, metastatic pattern, biochemical findings, and tissue biology rather than relying on one elevated metabolite.
Apply it
A young child has an adrenal-region mass and bone pain. Obtain urinary catecholamine metabolites as part of the evaluation, while arranging imaging and diagnostic confirmation rather than assuming that the mass location alone establishes neuroblastoma.
Common pitfall: An elevated metabolite supports a compatible diagnosis but does not supply stage, histology, or genomic risk. Normal metabolites also do not exclude all cases.
43.How do MYCN amplification and imaging findings contribute differently to neuroblastoma assessment?
MYCN amplification is an adverse biological feature that can alter risk assignment despite young age or localized disease. Amplification differs from ordinary expression or a single extra gene copy. Pretreatment INRG staging instead describes anatomical extent: localized tumors are L1 without image-defined risk factors and L2 when such factors, including important vessel encasement, are present. These imaging findings identify operative complexity and morbidity. Integrated risk combines stage with age, histology, MYCN, and other biology; resectability alone does not establish risk.
Apply it
An infant has a localized, MYCN-amplified tumor encasing major vessels. Recognize both adverse biology and an image-defined operative risk instead of allowing young age or absence of distant metastases to establish a low-risk plan.
Common pitfall: Localized disease can be biologically unfavorable and surgically hazardous. Pretreatment imaging stage, biological risk group, and completeness of resection answer different questions.
44.How do histology and laterality influence Wilms tumor management?
Wilms tumor risk assessment combines stage and histology. Favorable histology lacks anaplasia; diffuse anaplasia is associated with treatment resistance and poorer outcomes. Bilateral tumors at diagnosis constitute stage V, but the extent and histology of each kidney still matter. Bilateral disease requires planning that preserves functioning renal tissue where oncologically feasible, commonly using preoperative chemotherapy and nephron-sparing surgery. A renal mass therefore needs characterization beyond size alone. See [NCI Wilms Tumor and Other Childhood Kidney Tumors Treatment](https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdq).
Apply it
A child has tumors in both kidneys. Coordinate bilateral-disease treatment and renal-preservation planning rather than applying routine unilateral nephrectomy to both sides. If pathology shows diffuse anaplasia, incorporate its adverse implications.
Common pitfall: Stage V describes bilateral presentation, not a uniform prognosis. Favorable histology does not eliminate the importance of stage, and anaplasia is not simply another name for metastasis.
45.When can metastatic neuroblastoma in an infant have a distinctive course?
INRG stage MS requires age younger than 18 months at diagnosis, metastases confined to skin, liver, and/or bone marrow, and marrow tumor involvement below 10% of total nucleated cells. MIBG scintigraphy must be negative in both bone and bone marrow; bone metastases exclude MS. The primary tumor may meet L1 or L2 criteria. Anatomical stage is separate from biological risk, including MYCN amplification status. Some asymptomatic tumors with favorable biology can regress and may be observed. However, massive hepatic involvement can compromise breathing or other organ function and require treatment despite MS anatomical eligibility.
Apply it
A 10-month-old has an adrenal neuroblastoma with liver and skin metastases and 6% marrow tumor involvement. Staging shows no bone metastases or other metastatic sites. MIBG scintigraphy demonstrates uptake in the primary tumor but is negative in both bone and bone marrow. These findings establish stage MS eligibility. Favorable biology, including absence of MYCN amplification, supports the potential for regression, but progressive respiratory compromise from hepatomegaly requires intervention rather than continued observation.
Common pitfall: Marrow involvement below 10% and absence of bone metastases do not establish all MS criteria: negative bone and bone-marrow MIBG findings are also required. Bone metastases, marrow involvement of 10% or more, or age 18 months or older excludes MS. MYCN amplification changes biological risk without itself changing anatomical stage. Potential spontaneous regression never justifies overlooking respiratory compromise or other threatened organ function.
46.How do pathology, staging, and local control fit together in osteosarcoma?
Osteosarcoma is defined by malignant mesenchymal cells producing osteoid or immature bone. Plan biopsy with the orthopedic oncology team because its tract affects definitive surgery. Local MRI maps bone and soft-tissue extent and skip lesions; chest CT evaluates pulmonary metastases, with additional skeletal assessment as indicated. Conventional high-grade disease requires systemic chemotherapy plus complete surgical local control because imaging can miss microscopic systemic disease. Histological chemotherapy response informs prognosis but does not replace adequate resection. Selected low-grade variants require different management.
Apply it
An adolescent has an aggressive distal femoral lesion. Coordinate biopsy, confirm malignant osteoid, obtain local MRI and systemic staging, and explain why complete removal of a localized high-grade tumor does not make chemotherapy unnecessary.
Common pitfall: Calcification or reactive bone is not malignant osteoid. Local MRI does not complete systemic staging, and high-grade treatment principles should not be applied indiscriminately to low-grade variants.
NCI: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment
47.Why does medulloblastoma require assessment beyond the primary brain mass?
Medulloblastoma is a CNS embryonal tumor that can disseminate through cerebrospinal fluid. Staging therefore assesses the neuraxis, including brain and spinal imaging and appropriately timed CSF cytology when safe. Integrated classification includes WNT-activated, SHH-activated, and non-WNT/non-SHH disease, with group 3 and group 4 biology distinguished by molecular assessment. Prognosis and treatment also depend on age, dissemination, and residual disease. See [NCI Childhood Medulloblastoma and Other CNS Embryonal Tumors](https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq).
Apply it
A child undergoes resection of a cerebellar medulloblastoma. Assess spinal dissemination and molecular classification rather than assigning risk solely from the extent of the primary resection.
Common pitfall: A localized postoperative brain image does not establish absence of neuraxis disease. Lumbar puncture must account for intracranial pressure and postoperative timing rather than being performed automatically at presentation.
48.Which findings distinguish Ewing sarcoma from osteosarcoma?
Ewing sarcoma is a small round cell sarcoma commonly driven by an EWSR1::FLI1 fusion from t(11;22). Membranous CD99 supports the diagnosis but is not specific; morphology and molecular findings must agree. Osteosarcoma is instead defined by malignant osteoid production. Both require systemic assessment and coordinated local control, but their pathological classification and treatment regimens differ. See [NCI Ewing Sarcoma Treatment](https://www.cancer.gov/types/bone/hp/ewing-treatment-pdq).
Apply it
A pelvic bone tumor contains small round cells with diffuse membranous CD99 and an EWSR1::FLI1 fusion. This supports Ewing sarcoma, whereas malignant cells directly producing osteoid would support osteosarcoma.
Common pitfall: CD99 positivity alone does not establish Ewing sarcoma. An EWSR1 rearrangement also requires identification of the relevant fusion partner and pathological context.
49.Which retinoblastoma presentations raise concern for a heritable RB1 alteration?
Bilateral or multifocal retinoblastoma strongly suggests a heritable RB1 predisposition, but unilateral disease does not exclude it. Germline evaluation informs surveillance of the unaffected eye, family counseling, and assessment of relatives, as well as long-term second-cancer risk. Tumor and constitutional testing may be interpreted together to clarify risk, including mosaicism. Absence of a family history is not reassuring enough to exclude hereditary disease because a pathogenic alteration may arise de novo.
Apply it
A child has bilateral retinoblastoma and no affected relatives. Arrange genetic counseling and constitutional RB1 assessment rather than concluding that the disease is nonhereditary because both parents have normal vision and no known tumor history.
Common pitfall: Heritable does not require an affected parent. Unilateral disease also cannot be assumed nonheritable without appropriate clinical and genetic assessment of the individual child.
50.What distinguishes trilateral retinoblastoma from ocular metastatic spread?
Trilateral retinoblastoma refers to heritable retinoblastoma associated with an intracranial midline embryonal tumor, most often in the pineal region. The intracranial lesion is a distinct primary tumor rather than simply extension of an ocular mass. This distinction affects evaluation, prognosis, and treatment planning. Brain MRI is relevant to initial assessment in the appropriate setting, but ongoing screening practices require careful interpretation of specialist guidance rather than assuming every child needs an identical indefinite imaging schedule.
Apply it
A child with bilateral retinoblastoma has a pineal-region mass on brain MRI. Consider trilateral retinoblastoma and evaluate it as an associated intracranial primary rather than automatically labeling it direct extension through the optic nerve.
Common pitfall: The third tumor is not a third eye lesion. Its recognition depends on the hereditary disease context and intracranial location, not merely any abnormal brain imaging finding.
51.How do life preservation, ocular salvage, and visual potential shape retinoblastoma treatment?
Retinoblastoma treatment prioritizes survival while seeking eye preservation and useful vision when safely achievable. Tumor burden, laterality, seeding, location, and suspected extraocular extension influence selection among focal therapy, systemic or local chemotherapy approaches, and enucleation. An eye with extensive tumor and little visual potential may require enucleation despite available eye-salvage techniques. Pathological examination of an enucleated eye also identifies high-risk features that can change systemic management; ocular removal is therefore both therapeutic and informative.
Apply it
One eye contains extensive retinoblastoma with poor visual potential, while the other has a small treatable lesion. Discuss different strategies for each eye, preserving useful vision where feasible without allowing cosmetic goals to compromise cancer control.
Common pitfall: Eye preservation and vision preservation are different outcomes. Repeated salvage attempts should not delay necessary definitive treatment when the child's oncologic safety is at risk.
Hematopoietic Stem-Cell Transplant (HSCT)9%
52.How is the probability of an HLA-matched full sibling calculated?
Under the standard Mendelian model, each full sibling has a one-in-four chance of inheriting the same two parental HLA haplotypes as the patient. For multiple siblings, calculate the chance of no match and subtract it from one. With n independently considered full siblings, the probability of at least one match is 1 − (3/4)^n. This estimates HLA identity only; donor health, inherited disease status, age, and other suitability criteria still require assessment.
Apply it
A patient has two full siblings. Under the stated inheritance assumptions, the chance that at least one is HLA-identical is 1 − (3/4)^2, or 43.75%, before considering whether either matched sibling is otherwise an appropriate donor.
Common pitfall: Adding 25% for each sibling overestimates the probability. HLA identity also does not establish freedom from the patient's inherited disorder or overall donor suitability.
NCI: Pediatric Allogeneic Hematopoietic Stem Cell Transplant
53.Which trade-offs distinguish marrow, peripheral-blood, and cord-blood grafts?
Stem-cell source affects available cell dose, speed of hematopoietic recovery, immune-cell composition, and graft-versus-host disease risk. Peripheral-blood grafts generally provide more cells and faster recovery but can increase chronic GVHD compared with marrow in relevant settings. Cord blood offers rapid availability and different matching flexibility, but limited cell dose and slower recovery can be important constraints. Source selection integrates disease, recipient size, donor options, urgency, and transplant strategy rather than ranking one source as universally superior.
Apply it
A small child and a large adolescent have different available cord-blood cell doses per kilogram. Consider dose adequacy and recovery risks alongside matching and urgency rather than choosing the same source solely because both units are available immediately.
Common pitfall: An available graft is not automatically an adequate graft. Cell dose, matching, disease context, and GVHD risk must be considered together when comparing sources.
NCI: Pediatric Allogeneic Hematopoietic Stem Cell Transplant
54.Why can an allogeneic graft reduce leukemia relapse independently of conditioning?
Donor immune cells can recognize and eliminate residual malignant recipient cells, producing a graft-versus-leukemia effect. This immune contribution distinguishes allogeneic transplantation from merely delivering high-dose chemotherapy followed by blood-cell rescue. The same donor alloreactivity can injure normal recipient tissues, creating a tension between antileukemic activity and graft-versus-host disease. The two effects are related but not identical, and severe GVHD is not a desirable treatment endpoint. Relapse prevention must be balanced against transplant-related morbidity and mortality.
Apply it
A family asks why an allogeneic transplant differs from autologous rescue for leukemia. Explain the additional donor immune effect against residual leukemia while also discussing the possibility of immune injury to healthy recipient tissues.
Common pitfall: Graft-versus-leukemia activity does not mean more GVHD is always better. Autologous transplantation also does not provide the same donor-versus-recipient immune mechanism.
NCI: Pediatric Allogeneic Hematopoietic Stem Cell Transplant
55.What mechanism and organ pattern suggest acute graft-versus-host disease?
Acute graft-versus-host disease occurs when immunocompetent donor cells attack recipient tissues after allogeneic transplantation. Common target organs are skin, gastrointestinal tract, and liver, producing rash, diarrhea, and cholestatic liver abnormalities. Timing alone does not establish the diagnosis, because infections and drug toxicity can produce similar findings and acute features can occur beyond traditional time boundaries. Evaluation integrates organ pattern, severity, competing diagnoses, and selected biopsy findings rather than labeling every post-transplant rash as GVHD.
Apply it
An allogeneic transplant recipient develops a spreading rash and substantial watery diarrhea. Assess acute GVHD while investigating infections and medication toxicity, because the combined target-organ pattern is suggestive but does not eliminate competing explanations.
Common pitfall: GVHD reflects donor attack on the recipient, whereas graft rejection involves recipient immunity against the graft. The mechanisms should not be reversed when explaining post-transplant complications.
NCI: Complications, GVHD and Late Effects After Pediatric HSCT
56.Which findings meet pediatric criteria for sinusoidal obstruction syndrome after transplantation?
Pediatric EBMT criteria have no onset-time restriction and require at least two qualifying findings after excluding alternative causes: unexplained consumptive, transfusion-refractory thrombocytopenia; otherwise unexplained weight gain over three consecutive days despite diuretics or greater than 5% above baseline; hepatomegaly above baseline; ascites above baseline; or bilirubin rising from baseline over three consecutive days or reaching at least 2 mg/dL within 72 hours. Confirm new hepatic enlargement or ascites against baseline, preferably with imaging. Platelet refractoriness requires poor responses or otherwise unexplained consumption, not merely frequent transfusion. Normal bilirubin does not exclude pediatric disease.
Apply it
A child gains 6% above baseline, develops new ultrasound-confirmed ascites and hepatomegaly, and repeatedly has minimal one-hour platelet increments despite adequate doses. This meets several qualifying findings even with normal bilirubin; assess promptly for sinusoidal obstruction and organ dysfunction.
Common pitfall: Baseline hepatomegaly and ascites do not count as newly increased findings. Frequent platelet ordering alone does not demonstrate refractoriness, and an adult jaundice requirement can miss pediatric anicteric disease.
NCI: Complications, GVHD and Late Effects After Pediatric HSCT
57.Why does infection risk persist after neutrophil engraftment?
Neutrophil recovery marks only one component of immune reconstitution. T-cell and B-cell recovery can remain delayed, particularly with graft-versus-host disease and immunosuppressive therapy, leaving susceptibility to viral, fungal, and other opportunistic infections. Infection prevention and surveillance must therefore reflect transplant phase, immune deficits, donor-recipient factors, and current treatment rather than the neutrophil count alone. A patient with normal neutrophil numbers may still have substantial functional immune impairment and require ongoing prophylaxis or monitoring.
Apply it
A child has a normal neutrophil count after allogeneic transplantation but remains on substantial immunosuppression for GVHD. Continue risk-based infection prevention and monitoring rather than assuming that engraftment has restored normal antiviral and antifungal defenses.
Common pitfall: Engraftment and complete immune recovery are different milestones. Stopping preventive measures solely because the absolute neutrophil count normalizes can overlook prolonged adaptive immune deficits.
NCI: Complications, GVHD and Late Effects After Pediatric HSCT
Core Knowledge in Scholarly Activities5%
58.How should effect size, precision, and confounding be evaluated together?
Relative risk divides treated by comparison-group risk; absolute risk reduction subtracts treated risk from control risk. Their interpretation requires denominators and a follow-up interval. The reciprocal of absolute reduction estimates NNT for that interval. A confidence interval describes precision: the null is 1 for a risk ratio and 0 for a risk difference, and an interval spanning the null does not prove equivalence. In observational studies, confounding arises when a factor is associated with treatment and outcome without being an intermediate causal step. Stratification or appropriate regression can address measured confounders but cannot guarantee removal of bias.
Apply it
In a hypothetical two-year trial, relapse in 10 of 100 treated children versus 20 of 100 controls gives RR 0.50, absolute reduction 10 percentage points, and NNT 10. In an observational transplant comparison, first assess whether refractory disease influenced both transplant selection and survival.
Common pitfall: A 50% relative reduction is not a 50-percentage-point reduction. Wide confidence intervals leave uncertainty, and statistical adjustment neither establishes causation nor repairs unmeasured confounding.
CDC Field Epidemiology Manual: Analyzing and Interpreting Data · Endogeneity in Logistic Regression Models - Volume 11, Number 3—March 2005 - Emerging Infectious Diseases journal - CDC
59.How do parental permission and child assent protect pediatric research participants?
Parental permission and child assent are distinct protections. Assent is the child's affirmative agreement, assessed according to age, maturity, and psychological state; silence or failure to object is insufficient. The IRB determines whether assent is required and whether a permissible exception applies. One exception concerns an important prospect of direct benefit available only through the research. Research procedures must also satisfy the applicable risk-benefit category; parental willingness alone does not make a procedure approvable. These principles are specified in [HHS Subpart D](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/common-rule-subpart-d/index.html).
Apply it
A capable adolescent agrees to cancer treatment but refuses an optional research-only blood collection without direct benefit. Respect the refusal when assent is required, even if a parent has signed permission.
Common pitfall: Consent to clinical treatment is not automatic agreement to optional research. Do not interpret dependence on the clinical team, parental enthusiasm, or absence of protest as affirmative assent.
60.How should a quality-improvement project connect its aim, measures, and tests of change?
Define a specific population, measurable aim, and time frame. Use process measures to track how care is delivered, outcome measures to assess patient or system results, and balancing measures to detect unintended consequences. Test a change on a small scale with Plan-Do-Study-Act: predict and plan, implement, study observations against the prediction, then adopt, adapt, or abandon the change. Plot measures over time rather than relying on one before-and-after average. The [IHI Model for Improvement](https://www.ihi.org/library/model-for-improvement) and its [measurement guidance](https://www.ihi.org/library/model-for-improvement/establishing-measures) describe this approach.
Apply it
A service aims to improve timely antibiotics for eligible febrile neutropenic patients over six months. Track the fraction meeting its chosen timing target as a process measure, septic deterioration as an outcome, and unnecessary broad-spectrum exposure as a balancing measure. Test a triage change on one shift before expanding.
Common pitfall: An improved process measure does not by itself prove improved clinical outcomes. A faster workflow can introduce harms, so assess balancing measures and trends over time.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official detailed outline as the full scope. Extend these selections to additional erythrocyte disorders, immunoregulatory diseases, acquired coagulopathies, Hodgkin lymphoma, other marrow-failure syndromes, and additional solid tumors.
- Allocate the largest study blocks to Solid Tumors, General Oncology Issues, Erythrocytes, and Hematologic Malignancies while retaining every smaller domain.
- Practise paired discriminators: destruction versus production failure, platelet adhesion versus aggregation defects, quantitative versus qualitative VWD, morphologic remission versus MRD clearance, and engraftment versus immune recovery.
- Rehearse operational thresholds for sickle cell cerebrovascular care, aplastic-anemia severity, pediatric ITP corticosteroid duration, persistent febrile neutropenia, stage MS neuroblastoma, and pediatric sinusoidal obstruction syndrome.
- Link each cancer's anatomy, pathology, molecular biology, stage, treatment response, and local-control requirements rather than memorizing isolated markers.
- Compare anticoagulants by mechanism, clearance, monitoring, reversibility, and the child's bleeding and procedural risks.
- Distinguish component-processing indications from acute transfusion-reaction management, and practise the immediate response to fever with hypotension or hemoglobinuria.
- Practise effect calculations, confidence-interval interpretation, confounding assessment, pediatric research protections, and quality-improvement measurement.
A practical preparation plan
1. Map the complete initial-certification scope
Read the official outline's initial-certification column and detailed subdomains. Mark each topic as secure, uncertain, or unreviewed. Use the published approximate weights to distribute study time, without dropping lower-weight domains.
2. Connect mechanisms with discriminating findings
For each concept, explain the causal mechanism, the finding that separates its closest alternative, and the decision that changes. Rework mini-cases by changing one feature, such as the reticulocyte count, platelet-function pattern, MRD result, or transplant immune status.
3. Rehearse urgent decisions
Practise what must occur promptly in sickle cell neurologic events, suspected APL, high-risk fever and neutropenia, tumor lysis, and suspected acute hemolytic transfusion reactions. State numerical thresholds and treatment targets where they determine action, and distinguish parallel emergency care from subsequent classification.
4. Use the questions diagnostically
Complete the 20 questions without consulting explanations. For every option, identify the feature that makes it appropriate or inappropriate. Classify errors as a mechanism gap, missed cue, calculation error, or unsupported management assumption.
5. Expand weak areas and revisit actively
Return to the relevant clinical reference and the full outline for weak or uncovered topics. Use spaced flashcard review, then answer a fresh case in your own words to confirm that recall transfers to clinical reasoning.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABP Pediatric Hematology-Oncology Content Outline
- ASPHO: Certification in Pediatric Hematology/Oncology
- ABMS: American Board of Pediatrics
- NHLBI: Iron-Deficiency Anemia
- GeneReviews: EPB42-Related Hereditary Spherocytosis
- ASH Sickle Cell Disease Cerebrovascular Guidelines Snapshot
- ASH: Managing Cerebrovascular Disease in Sickle Cell Disease
- GeneReviews: Chronic Granulomatous Disease
- ASH: Management of Immune Thrombocytopenia Pocket Guide
- ASH Clinical Practice Guidelines on Immune Thrombocytopenia
- ASH ISTH NHF WFH: VWD Diagnosis Executive Summary
- CDC: Diagnosing Hemophilia
- GeneReviews: Fanconi Anemia
- Canadian Blood Services: Irradiated, Washed and CMV Seronegative Blood Components
- eviQ: Prevention of Tumour Lysis Syndrome
- COG: Pediatric Fever and Neutropenia Guideline, 2023 Update
- NCI: Late Effects of Treatment for Childhood Cancer
- NCI: Childhood Acute Lymphoblastic Leukemia Treatment
- NCI: Childhood Acute Myeloid Leukemia Treatment
- NCI: Neuroblastoma Treatment
- NCI: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment
- NCI: Retinoblastoma Treatment
- NCI: Pediatric Allogeneic Hematopoietic Stem Cell Transplant
- NCI: Complications, GVHD and Late Effects After Pediatric HSCT
- CDC Field Epidemiology Manual: Analyzing and Interpreting Data
- 9789241596107-annex4.pdf
- ida_assessment_prevention_control.pdf
- 103946s5103lbl.pdf
- Childhood APL Treatment (PDQ®) - NCI
- Endogeneity in Logistic Regression Models - Volume 11, Number 3—March 2005 - Emerging Infectious Diseases journal - CDC
- Irradiated, washed and CMV seronegative blood components | Professional Education
- 020164s129lbl.pdf
- Childhood Non-Hodgkin Lymphoma Treatment (PDQ®) - NCI
- Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®) - NCI
- Ewing Sarcoma Treatment (PDQ®) - NCI
- Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) - NCI
- JCI - A novel leukocyte adhesion deficiency caused by expressed but nonfunctional β2 integrins Mac-1 and LFA-1
- Client Challenge
- ash-cpg-aplastic-anemia-pocket-guide-6-panel-0320-nocropmarks.pdf
- Transfusion reactions | Professional Education
- These highlights do not include all the information needed to use Elitek safely and effectively. See full prescribing information for Elitek®. ELITEK (rasburicase) for injection, for intravenous useInitial U.S. Approval: 2002
- COG_LTFU_Guidelines_Only_v6.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.